Withdrawn Clinical Trial Explored p53-Targeted Immunotherapy for Recurrent Breast Cancer

Recurrence of breast cancer after initial endocrine therapy remains a significant clinical challenge, often leading to limited treatment options. While aromatase inhibitors (AIs) are a cornerstone of endocrine therapy, patients can develop resistance or disease progression. There is a critical need for innovative strategies to improve long-term outcomes for these patients. This study aimed to evaluate if combining a p53-peptide pulsed dendritic cell (DC) vaccine with standard aromatase inhibitor therapy could improve time to progression and induce a measurable immune response in patients with recurrent breast cancer.

This clinical trial was withdrawn before completion, and consequently, no results regarding efficacy, safety, or immune response were reported. Therefore, no data on time to progression, objective response rate, or specific immune markers could be analyzed or presented. > The primary objective of this study was to investigate the time to progression in breast cancer patients receiving the p53-peptide pulsed dendritic cell vaccine in combination with an aromatase inhibitor. The study's withdrawal means that the potential clinical benefits or immunological effects of this specific combination therapy remain undetermined. The intended comparison between the DC vaccine plus AI group and the AI-only control group could not be performed due to the premature termination of the trial.